Ambulero Revenue and Competitors
Estimated Revenue & Valuation
- Ambulero's estimated annual revenue is currently $310k per year.
- Ambulero's estimated revenue per employee is $77,500
- Ambulero's total funding is $5.5M.
Employee Data
- Ambulero has 4 Employees.
- Ambulero grew their employee count by 0% last year.
Ambulero's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Operations Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
Ambulero Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.3M | 99 | 5% | N/A | N/A |
#2 | $1.1M | 7 | -30% | N/A | N/A |
#3 | $3.7M | 24 | 4% | N/A | N/A |
#4 | $4.3M | 28 | -3% | N/A | N/A |
#5 | $2.5M | 16 | N/A | N/A | N/A |
#6 | $0.8M | 5 | 0% | N/A | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $2.5M | 16 | 7% | N/A | N/A |
#9 | $1.4M | 9 | -25% | N/A | N/A |
#10 | $0.6M | 4 | 0% | N/A | N/A |
What Is Ambulero?
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion molecule E-selectin using different cell and synthetic vector technologies. We work on rare vascular diseases as well as more common indications effecting large patient populations.
keywords:N/A
$5.5M
Total Funding
4
Number of Employees
$310k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ambulero News
2022-04-20 - Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs - ResearchAndMarkets.com
AMB-301: Ambulero. AMB-301 is a promising gene therapy candidate for enhancing blood vessel formation, restoring tissue integrity,...
2022-04-06 - Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight
... Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, ... the orphan drug status for Ambulero's gene therapy candidate,...
Other Companies in Miami
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 4 | N/A | N/A |
#2 | $0.3M | 4 | N/A | N/A |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.5M | 4 | -33% | N/A |